Evaluating the potential public health impact of a Staphylococcus aureus vaccine through use of population-based surveillance for invasive methicillin-resistant S. aureus disease in the United States

Abstract We evaluated the potential effects of a hypothetical vaccine in preventing invasive methicillin-resistant Staphylococcus aureus (MRSA) disease in the United States. Using an active, population-based surveillance program, we estimated baseline disease rates in the United States and compared...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2009-08, Vol.27 (37), p.5061-5068
Main Authors: Lucero, Cynthia A, Hageman, Jeffrey, Zell, Elizabeth R, Bulens, Sandra, Nadle, Joelle, Petit, Susan, Gershman, Ken, Ray, Susan, Harrison, Lee H, Lynfield, Ruth, Dumyati, Ghinwa, Townes, John M, Schaffner, William, Fridkin, Scott K
Format: Article
Language:English
Subjects:
Adolescent
Adult
Age
Aged
Allergy and Immunology
Applied microbiology
Bacteriology
Biological and medical sciences
Cost of Illness
Disease Outbreaks - prevention & control
Fundamental and applied biological sciences. Psychology
Humans
Immunization Programs
Infection Control
Methicillin-resistant Staphylococcus aureus
Methicillin-Resistant Staphylococcus aureus - isolation & purification
Microbiology
Middle Aged
Miscellaneous
Population Surveillance
Potential benefits
Sensitivity and Specificity
Staphylococcal Infections - epidemiology
Staphylococcal Infections - prevention & control
Staphylococcal vaccines
Staphylococcal Vaccines - immunology
Staphylococcus aureus
United States - epidemiology
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract We evaluated the potential effects of a hypothetical vaccine in preventing invasive methicillin-resistant Staphylococcus aureus (MRSA) disease in the United States. Using an active, population-based surveillance program, we estimated baseline disease rates in the United States and compared three distinct vaccination strategies which targeted adults ≥65 years of age, persons at risk for recurrent invasive infection, and patients at hospital discharge. The strategies were projected to reduce the burden of invasive MRSA disease by 12.1%, 13.9% and 17.6%, respectively; with the strategy of vaccinating both adults ≥65 years of age and all adults at hospital discharge having the greatest impact per dose. Our data suggest that availability of an effective S. aureus vaccine could result in substantial reductions in invasive MRSA disease incidence. As candidate vaccines are evaluated, these data will be important in determining the optimal vaccination strategy.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2009.06.055